Request for non-reimbursed use of Pahtension in Loop's pts

not approved

Add 20 more cases, including Previmis, My-Rept, Xeljanz by the HIRA

Application for Pahtension 20mg was rejected for non-reimbursed patients with systemic erythema lupus accompanied by immunosuppressants, vasculitis that does not improve even with antibiotics, and peripheral ulcers.

 

The HIRA is receiving applications in advance for use exceeding the MFDS' permission to prevent the use of drugs that lack medical evidence or are concerned about safety.

 

According to the details recently released by the HIRA, a total of 237 cumulative cases were rejected due to insufficient medical evidence for the submitted data, including Pahtension.

 

Cases added this time include Previmis 240mg tab, Previmis 480mg tab, and Previmis inj, which will be non-reimbursed to pediatric and adolescent patients receiving hematopoietic stem cell transplantation.

 

The request to prescribe My-Rept 250mg to Sjogren's syndrome patient with steroid dependence that recur during steroid loss after diagnosis of MCD and renal syndrome was also rejected.

 

After hematopoietic stem cell transplantation, prescriptions of R-A 10mg and R-A 20mg were also rejected for patients with BK virus-related hemorrhagic cystitis who did not respond to existing antiviral drugs or could not be used as side effects of existing antiviral drugs.

 

All attempts to prescribe Premina 0.625mg and Premina 3mg to patients with hemorrhagic cystitis who do not respond to existing treatment after hematopoietic stem cell transplantation or after high-dose cyclophosphamide treatment have not been approved.

 

Among patients with circular hair loss, frontal hair loss, or systemic hair loss aged 8 years or older, it was also rejected to prescribe Xeljanz to patients with severe intractable skin lesions or interstitial pneumonia who do not respond to SALT score changes of less than 25% or high dose glucocorticoid and at least two immunomodulatory treatment.

 

Approval to prescribe Previmis 240mg and Previmis 480mg was also rejected if there was no improvement in the use of other antiviral drugs for more than two weeks due to giant cell virus infection and peripheral organ disease after hematopoietic stem cell transplantation.

 

Among children with persistent tachycardia after heart transplantation, approval to prescribe Procoralan 5mg was also rejected to patients with tachycardia persistent tachycardia despite the use of drugs such as beta blockers.